LCTX Relative Valuation
LCTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LCTX is overvalued; if below, it's undervalued.
Historical Valuation
Lineage Cell Therapeutics Inc (LCTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.75. The fair price of Lineage Cell Therapeutics Inc (LCTX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.74
Fair
-17.21
PE
1Y
3Y
5Y
Trailing
Forward
-14.12
EV/EBITDA
Lineage Cell Therapeutics Inc. (LCTX) has a current EV/EBITDA of -14.12. The 5-year average EV/EBITDA is -13.80. The thresholds are as follows: Strongly Undervalued below -65.89, Undervalued between -65.89 and -39.84, Fairly Valued between 12.25 and -39.84, Overvalued between 12.25 and 38.29, and Strongly Overvalued above 38.29. The current Forward EV/EBITDA of -14.12 falls within the Historic Trend Line -Fairly Valued range.
-17.08
EV/EBIT
Lineage Cell Therapeutics Inc. (LCTX) has a current EV/EBIT of -17.08. The 5-year average EV/EBIT is -7.60. The thresholds are as follows: Strongly Undervalued below -14.66, Undervalued between -14.66 and -11.13, Fairly Valued between -4.07 and -11.13, Overvalued between -4.07 and -0.54, and Strongly Overvalued above -0.54. The current Forward EV/EBIT of -17.08 falls within the Strongly Undervalued range.
31.36
PS
Lineage Cell Therapeutics Inc. (LCTX) has a current PS of 31.36. The 5-year average PS is 42.77. The thresholds are as follows: Strongly Undervalued below -57.34, Undervalued between -57.34 and -7.29, Fairly Valued between 92.82 and -7.29, Overvalued between 92.82 and 142.88, and Strongly Overvalued above 142.88. The current Forward PS of 31.36 falls within the Historic Trend Line -Fairly Valued range.
-22.85
P/OCF
Lineage Cell Therapeutics Inc. (LCTX) has a current P/OCF of -22.85. The 5-year average P/OCF is -4.09. The thresholds are as follows: Strongly Undervalued below -59.46, Undervalued between -59.46 and -31.77, Fairly Valued between 23.59 and -31.77, Overvalued between 23.59 and 51.27, and Strongly Overvalued above 51.27. The current Forward P/OCF of -22.85 falls within the Historic Trend Line -Fairly Valued range.
-31.59
P/FCF
Lineage Cell Therapeutics Inc. (LCTX) has a current P/FCF of -31.59. The 5-year average P/FCF is -24.90. The thresholds are as follows: Strongly Undervalued below -168.22, Undervalued between -168.22 and -96.56, Fairly Valued between 46.77 and -96.56, Overvalued between 46.77 and 118.43, and Strongly Overvalued above 118.43. The current Forward P/FCF of -31.59 falls within the Historic Trend Line -Fairly Valued range.
Lineage Cell Therapeutics Inc (LCTX) has a current Price-to-Book (P/B) ratio of 18.18. Compared to its 3-year average P/B ratio of 3.89 , the current P/B ratio is approximately 367.40% higher. Relative to its 5-year average P/B ratio of 3.60, the current P/B ratio is about 405.64% higher. Lineage Cell Therapeutics Inc (LCTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -12.23%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -8.73% , the current FCF yield is about -100.00% lower.
18.18
P/B
Median3y
3.89
Median5y
3.60
-5.13
FCF Yield
Median3y
-12.23
Median5y
-8.73
Competitors Valuation Multiple
The average P/S ratio for LCTX's competitors is 0.00, providing a benchmark for relative valuation. Lineage Cell Therapeutics Inc Corp (LCTX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -2.59%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LCTX increased by 246.27% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -79.41 to -808.26.
The secondary factor is the Revenue Growth, contributed -2.59%to the performance.
Overall, the performance of LCTX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Lineage Cell Therapeutics Inc (LCTX) currently overvalued or undervalued?
What is Lineage Cell Therapeutics Inc (LCTX) fair value?
How does LCTX's valuation metrics compare to the industry average?
What is the current P/B ratio for Lineage Cell Therapeutics Inc (LCTX) as of Dec 05 2025?
What is the current FCF Yield for Lineage Cell Therapeutics Inc (LCTX) as of Dec 05 2025?
What is the current Forward P/E ratio for Lineage Cell Therapeutics Inc (LCTX) as of Dec 05 2025?